Etoposide

For research use only.

Catalog No.S1225 Synonyms: VP-16, VP-16213

144 publications

Etoposide Chemical Structure

Molecular Weight(MW): 588.56

Etoposide (VP-16, VP-16213) is a semisynthetic derivative of podophyllotoxin, which inhibits DNA synthesis via topoisomerase II inhibition activity. Etoposide induces autophagy, mitophagy and apoptosis.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 91 In stock
USD 70 In stock
USD 280 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Etoposide has been cited by 144 publications

Purity & Quality Control

Choose Selective Antineoplastic and Immunosuppressive Antibiotics Inhibitors

Biological Activity

Description Etoposide (VP-16, VP-16213) is a semisynthetic derivative of podophyllotoxin, which inhibits DNA synthesis via topoisomerase II inhibition activity. Etoposide induces autophagy, mitophagy and apoptosis.
Targets
Topo II [2]
(Cell-free assay)
In vitro

Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA, which induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle. [1] Etoposide inhibits the growth of murine angiosarcoma cell line (ISOS-1) in a 5 days-period with IC50 of 0.25 μg/mL. Cell growth of normal murine microvascular endothelial cells (mECs) is less sensitive to Etoposide with IC50 of 10 μg/mL). [2] Etoposide treated for 6 hr inhibits colonies of tetraploid variant of the human leukemic lymphoblast line CCRF-CEM with IC50 of 0.6 μM. [3] Etoposide treated for 2 hr inhibits growth of human pancreatic cancer cell line Y1, Y3, Y5, Y19, YM. YS, and YT with IC50s of 300 μg/mL, 300 μg/mL, 300 μg/mL, 91 μg/mL, 0.68 μg/mL, 300 μg/mL, 300 μg/mL, and 260 μg/mL, respectively. [4] Etoposide exposed for 1 hr inhibits growth of human glioma cell lines CL5, G142, G152, G111, and G5 with IC50 of 8, 9, 9.8, 10, and 15.8 μg/mL respectively for 12 days. Under same condition, the IC90 value is attained in cell lines CL5, G152, G142, and G111 at 26, 27, 32, and 33 μg/mL. Etoposide inhibition of topoisomerase II is homogeneous for each cell. The average inhibition rates are 15%, 21.8%, 31.8%, 41.5%, and 49.5% for 1, 2, 4, 8, and 16 μg Etoposide, respectively. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Kelly NVK4cZRRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTBwMUNihKnDueLCiUCuNFEh|ryP NVfZ[3ZFOjV7NkCyPFI>
KellyCis83 NIKwWVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTBwMUdihKnDueLCiUCuNFIh|ryP M3\E[lI2QTZyMkiy
SK-N-AS NFPFcVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTBwMkVihKnDueLCiUCuNFMh|ryP NELadIczPTl4MEK4Ni=>
SK-N-ASCis24 MnX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmiwTWM2OD1yLkW35qCKyrIkgJmwMlEyKM7:TR?= MlX1NlU6PjB{OEK=
U87 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\J[FAuPTBizszN M3HBfVQ5KGh? NYnHTmhv\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JJdpcWOqIHPhckBj\SCnbnjhcoNm\CCkeTDzbYxq[mmwaX6= NFS5clAzPTd3MEK3Ny=>
HCT116 NFX4eI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnle5MxNjVvMj61JO69VQ>? NXP4PVVJPDkEoHlCpC=> M3TjNGlEPTB;MT63N:KhyrIEoECuNlHDqM7:TR?= MWiyOVc1Pjd4Mx?=
HT-29 NWjG[G5jT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljNNE42NTJwNTFOwG0> M2PPd|Q5yqCqwrC= MkDNTWM2OD15LkNCpOKyyqBzLkC0xsDPxE1? MXiyOVc1Pjd4Mx?=
Caco2 NUHYTXVwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHv5XZQxNjVvMj61JO69VQ>? MXq0POKhcMLi MUDJR|UxRTdwMkdCpOKyyqBzLk[4xsDPxE1? NXz4UWdHOjV5NE[3OlM>
COLO 205 M{C4PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXSwMlUuOi53IN88US=> M3HPeVQ5yqCqwrC= MWPJR|UxRTFwNkJCpOKyyqByLkCyxsDPxE1? M{ewWFI2PzR4N{[z
SW480 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDoV5VSOC53LUKuOUDPxE1? NFf6[|Q1QMLiaNMg Mly1TWM2OD12LkmyxsDDucLiMD6zN:Kh|ryP M2j1[lI2PzR4N{[z
HEK293T NXPsSWQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDlNU02KM7:TR?= MVy0POKhcMLi NFi4b3NKSzVyPUKuOFLDqMLzwrCwMlA2yqEQvF2= NH7BUlkzPTd2Nke2Ny=>
Hep3B  NIH4SIpHfW6ldHnvckBCe3OjeR?= MYOxNEDPxE1? Mm\LOFjDqGkEoB?= MmHpdoVlfWOnczD0bIUh\W6qYX7jbY5oKGWoZnXjeEBw\iCETWCtOi=> NU[1bYozOjV4M{O1OlQ>
Hep3B  M1HFUWZ2dmO2aX;uJGF{e2G7 M33ESVAvOS1zMDFOwG0> MU[yOEBp NUXTeWF6e3WycILld5NmeyC2aHWg[ZhxemW|c3nvckBw\iCqZYDjbYRqdiCvUl7B M4rJeVI2PjN|NU[0
HEK293 MmDJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTdwMUVCpOKyyqByLkO2xsDPxE1? M3TGRVI2PjB|MUKy
DU145 NHPiRoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrpdXVTUUN3ME2yMlI5yqEEsdMgNE4xPMLizszN MoW4NlU3ODNzMkK=
HCT15 M1r2cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTPV3dKUUN3ME2wMlgyyqEEsdMgNE4xOcLizszN M4DqO|I2PjB|MUKy
T47D MmrpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HsT2lEPTB;Mz6xPOKhyrIEoECuNVHDqM7:TR?= NYDnT2NWOjV4MEOxNlI>
SMMC-7721 M2ixSGZ2dmO2aX;uJGF{e2G7 MWO0NEDPxE1? NVXtVpZmPDhiaB?= NGLQXWNFVVOR MVvpcoR2[2W|IN8zTFJCYCCob3PpJIZwem2jdHnvci=> M1zEV|I2PTR2M{[x
MDA-MB-231 NES2U3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXG3NuKhcA>? Mmr0TWM2OD1{MT6yxsDDucLiND6yxsDPxE1? M3fN[VI2PDh4MkG5
MCF-7 M4D3fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\MZlczyqCq MmDCTWM2OD1zMD65xsDDucLiMj6xxsDPxE1? MX6yOVQ5PjJzOR?=
Jurkat M{\PTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWW3NuKhcA>? NILVWHFKSzVyPUGuNuKhyrIEoEGuOeKh|ryP NXnXXZFEOjV2OE[yNVk>
HeLa MljWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn7yO|LDqGh? NYnUeIVXUUN3ME2zMlnDqMLzwrCyMlPDqM7:TR?= NEPKeoYzPTR6NkKxPS=>
MCF7  MnK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\ZUVUuOTByIN88US=> M2q0d|ch\A>? M125T4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NE\tWYkzPTR5Mk[xPS=>
K562 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTNR4o4OsLiaB?= MlzGTWM2OD1yLkK5xsDPxE1? M17LPFI2Ojh{NkWz
K/VP.5 NXjHVpFtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfuPWw4OsLiaB?= NVzVV5Q2UUN3ME20MlnDqM7:TR?= NIjWdZMzPTJ6Mk[1Ny=>
SH-EP  NYjuNnJ4TnWwY4Tpc44hSXO|YYm= M4rQdlIxyqEQvHevcYw> MkLZNlTDqGh? MX7pcoNz\WG|ZYOgeIhmKGW6cILld5Nqd25ib3[g[Y5ld2enbn;1d{BFTVCS Ml\aNlUzPjF7OEG=
SCC25 M1LFe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFz1[YszPMLiaB?= NGDOOmpKSzVyPUSzMlPDqMLzwrCxMlEzyqEQvF2= MmPWNlUzOjB5Mkm=
CAL27 NVnFeoUyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVP0bI52OjUEoHi= M4CycGlEPTB;NUKuNeKhyrIEoEGuNFnDqM7:TR?= NWHqdotMOjV{MkC3Nlk>
FaDu NVXFZ2NFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYCyOOKhcA>? NEnDT2pKSzVyPUK1Mlg6yqEEsdMgNU4yO8LizszN NUnPco5POjV{MkC3Nlk>
SCC25 MnS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\qSFQ5yqCq NFLleJRKSzVyPUKwMlg3yqEEsdMgNU4xP8LizszN MVmyOVIzODd{OR?=
CAL27 MoPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1W0fVQ5yqCq NEHScHlKSzVyPUG4MlI1yqEEsdMgNU4yPcLizszN MYmyOVIzODd{OR?=
FaDu MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFHTe281QMLiaB?= Mn\uTWM2OD14LkSzxsDDucLiMT6xN:Kh|ryP NEO3VWYzPTJ{MEeyPS=>
SCC25 NGGwN4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYO3NuKhcA>? MX3JR|UxRThwNEJCpOKyyqBzLkGxxsDPxE1? MkHLNlUzOjB5Mkm=
CAL27 M1\NXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW[3NuKhcA>? NWjY[|EyUUN3ME20MlI4yqEEsdMgNU4yPMLizszN NUnuXYJFOjV{MkC3Nlk>
FaDu M3fteGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX23NuKhcA>? MYnJR|UxRTVwMENCpOKyyqBzLkG1xsDPxE1? MnHlNlUzOjB5Mkm=
MCF-7 MlSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrC[5g1QMLiaNMg MUfEUXNQ MW\JR|UxRTdwMtMgxtHDqDBwONMg{txO NYfRdWpwOjV{MU[zO|g>
T-47D NH20TFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYq0POKhcMLi MonGSG1UVw>? MXLJR|UxRTdwN9MgxtHDqDBwN9Mg{txO MlHJNlUzOTZ|N{i=
MDA-MB-231 M2HEW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33FXFQ5yqCqwrC= MknLSG1UVw>? MYfJR|UxRTF{LklCpOKyyqBzLkFCpO69VQ>? MmrNNlUzOTZ|N{i=
DU145 NGP5cpdCeG:ydH;zbZMhSXO|YYm= MVixNE0yODBizszN NVry[ohHQCCq M{e0PWROW09? MmnMbY5lfWOnczDj[YxtKGSnYYToJJNq\26rZnnjZY51dHliaX6gZUB3\XK7IHzve{Bkd26lZX70doF1cW:w NYLLSIRpOjVzNEm2PFE>
DU145 stem-like M1zpbWFxd3C2b4Ppd{BCe3OjeR?= MWmxNE0yODBizszN Mnv3PEBp MlW0SG1UVw>? MVnpcoR2[2W|IHPlcIwh\GWjdHigbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NIr6[FczPTF2OU[4NS=>
DU145 MYnGeY5kfGmxbjDBd5NigQ>? M1H4dlExNTFyMDFOwG0> NHrmdFUzKGh? MWTEUXNQ M2fX[olv[3KnYYPld{B1cGVicFPIT|Eh\XiycnXzd4lwdiCjbnSg[IVkemWjc3XzJJRp\SCyQ1jLNUBmgHC{ZYPzbY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M3PyNVI2OTR7Nkix
DU145 stem-like NIOyPXBHfW6ldHnvckBCe3OjeR?= MmO0NVAuOTByIN88US=> MknJNkBp MXjEUXNQ MVTpcoNz\WG|ZYOgeIhmKHCFSFuxJIV5eHKnc4Ppc44h[W6mIHTlZ5Jm[XOnczD0bIUheEOKS{Gg[ZhxemW|c3nvckBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MX[yOVE1QTZ6MR?=
UW228-3 NGGxVHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\zNE4xOS1|MECg{txO M1W0OFQ5KGh? NUS3doVFTE2VTx?= M3i2e2lEPTB;MD65PeKh|ryP MUeyOVEyQTF6NR?=
NSCs MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\Wb5AxNjBzLUOwNEDPxE1? MVK0PEBp MVzEUXNQ M4OwO2lEPTB;MD6zMVPDqM7:TR?= NVHBVmN2OjVzMUmxPFU>
MKL-1  M1;xO2Z2dmO2aX;uJGF{e2G7 MUexNE0yODByIH7N MnfMOEBl M1HNfolv\HWlZYOgeIhmKGmwZIXjeIlwdiCxZjDNTGMuUSCneIDy[ZN{cW:w MVeyOVEyPjd3NB?=
MCF7 EV NXPQNppVTnWwY4Tpc44hSXO|YYm= MkLINVAuOTByIN88US=> NX\4S4dtOuLCiXi= MkK2bY5lfWOnczDwdo9lfWO2aX;uJI9nyqEQs1iyRXg> M1rZO|I2ODh6MkCz
MCF 7BMI1 NIftRYZHfW6ldHnvckBCe3OjeR?= NWGzUFN5OTBvMUCwJO69VQ>? NVzLO4N6OuLCiXi= NWWzcWk6cW6mdXPld{Bxem:mdXP0bY9vKG:owrFOt2gzSVh? NXXENopHOjVyOEiyNFM>
MCF7 EV NYf5ZlVPTnWwY4Tpc44hSXO|YYm= NHXYSJAyOC1zMECg{txO M2\oS|LjiImq Mkf4SXRQWCCrbnT1Z4V{KEGWTTDhZ5RqfmG2aX;u MVGyOVA5QDJyMx?=
MCF7 BMI1 MXjGeY5kfGmxbjDBd5NigQ>? MYCxNE0yODBizszN NID1NYQz6oDLaB?= M{DqWmVVV1BiaX7keYNmeyCDVF2gZYN1cX[jdHnvci=> NVnjTGpUOjVyOEiyNFM>
HepG2 NVvQWpJVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPpSG1UV8Li NWLtZ413UUN3ME2zNE4yPsLiwsJCpFAvPTEEoN88US=> NHjkVIczPTB5OEOxNS=>
MOLT-3 NF7xWJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LJXWROW00EoB?= MXPJR|UxRTBwMEWxxsDDucLiMD6wNFLDqM7:TR?= NXrtVHk2OjVyN{izNVE>
HT1080 NIm2bWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXGxMVExOCEQvF2= NV34VmZRPC9{ND:0PEBp MnvSSG1UV8Li M4Xzd4lv\HWlZYOgZ4VtdCCmZXH0bEB{cWewaX\pZ4FvfGy7IHnuJIEhfmW{eTDsc5ch[2:wY3XueJJifGmxbh?= MkntNlUxPzhyNkS=
HT1080 M3O4OmZ2dmO2aX;uJGF{e2G7 NISySnoxNjByMEGtNVAxKM7:TR?= NUnpSGJkOS1{NDDo MY\EUXNQyqB? MnfsbY5lfWOnczDwMZA2Oyi|ZYKxOUkhcW5iYn;0bEB1cW2nLTDhcoQh[2:wY3XueJJifGmxbj3k[ZBmdmSnboSgcYFvdmW{ M37iOVI2ODd6ME[0
HT1080 M{C0Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTLR2NbOC5yMECxMVExOCEQvF2= NHyycI0zPCCq MW\EUXNQyqB? MU\jZZV{\XNiYX6gbY5kemWjc3WgbY4hfGinIH71cYJmeiCxZjDj[YxteyCrbjDHNk9ONCC5aHns[UBl\WO{ZXHzbY5oKFNiYX7kJGcyKHCqYYPlJINmdGy| NFrXXJAzPTB5OEC2OC=>
HD-MY-Z MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjTfnliOjRxNEivO|IhcA>? M3\1UmlEPTExvK6xNFAh|ryP NEm3O3MzPTB2OEKzOi=>
DOHH-2 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1Kw[lI1KGh? MlfZTWM2OO,:nkGwNEDPxE1? MWCyOVA1QDJ|Nh?=
DOHH-2 NF\UcGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\4dGs1QCCq MW\JR|UxRTF7LkpCpO69VQ>? MWeyOVA1QDJ|Nh?=
DOHH-2 NHXxS3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;rO3Q4OiCq Mn7mTWM2OD13wrFOwG0> NXnFcnNlOjVyNEiyN|Y>
REH M{TKW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWOyOEBp NX2zcJVuUUN3ME2wMlAzP8LizszN MUSyOVA1QDJ|Nh?=
REH MlXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{fDelQ5KGh? MljHTWM2OD1yLkCxOOKh|ryP MYWyOVA1QDJ|Nh?=
REH NF\IZ3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEL0WHE4OiCq MYfJR|UxRTBwMEG1xsDPxE1? NIf3eXUzPTB2OEKzOi=>
HH MmjWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUeyOEBp M2qzXGlEPTB;MUC0MlfDqM7:TR?= NH;Yb4QzPTB2OEKzOi=>
HH M17sZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTPOFghcA>? NH6xPY9KSzVyPUS4MlbDqM7:TR?= M36wVFI2ODR6MkO2
HH NUDWcYx6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLRd2VbPzJiaB?= Ml;kTWM2OD1zND63xsDPxE1? NFvpWnAzPTB2OEKzOi=>
HuT-78 M3S0T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYiyOEBp M4D1SWlEPTB;OT6zxsDPxE1? NX:0emhxOjVyNEiyN|Y>
HuT-78 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPlNnY1QCCq Mlf5TWM2OD12LkRCpO69VQ>? M2XhV|I2ODR6MkO2
HuT-78 Ml;GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\1dlczKGh? NY\xdHFEUUN3ME20MlLDqM7:TR?= NWDnXWhDOjVyNEiyN|Y>
OPM-2 NVfuVnJST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4Pw[|I1KGh? MUnJR|UxRTJ2LkJCpO69VQ>? MWqyOVA1QDJ|Nh?=
OPM-2 NYDIUY1CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGG4[m01QCCq NY\kUJlHUUN3ME20xsDPxE1? NELPOokzPTB2OEKzOi=>
OPM-2 MmfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUW3NkBp MkXXTWM2OD1zLkRCpO69VQ>? M3:wO|I2ODR6MkO2
RPMI-8226 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jDTlI1KGh? MkXKTWM2OD1zME[uOuKh|ryP MlPwNlUxPDh{M{[=
RPMI-8226 M2jxcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXG0PEBp Mn60TWM2OD17MT6xxsDPxE1? NYTa[3dYOjVyNEiyN|Y>
RPMI-8226 Mn;HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWT0c5lKPzJiaB?= NX3WR4RiUUN3ME2xOE46yqEQvF2= NVz2eoNkOjVyNEiyN|Y>
U-266 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13Hb|I1KGh? MkjqTWM2OD16Nj6yxsDPxE1? NYHGWZJvOjVyNEiyN|Y>
U-266 NGT3XoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYW0PEBp Ml3FTWM2OD14OD60xsDPxE1? MknRNlUxPDh{M{[=
U-266 M{fKfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUe3NkBp Ml\ITWM2OD1{Nz60xsDPxE1? MWKyOVA1QDJ|Nh?=
Kelly NHXXc3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjuVG5DOC1zMDFOwG0> MUK3NuKhcA>? MX\JR|UxRTFwNUG4xsDPxE1? MnXYNlUxODh7MEC=
SH-SY5Y  NUHrWGRsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnT[HdNOC1zMDFOwG0> NHLiWJI4OsLiaB?= NF3TUYRKSzVyPUCuO|U1yqEQvF5CpC=> MWqyOVAxQDlyMB?=
SK-N-AS NWLacmZFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjwcYoxNTFyIN88US=> NEfGZ5Q4OsLiaB?= MYnJR|UxRTFwN{GyxsDPxE4EoB?= MUiyOVAxQDlyMB?=
SK-N-DZ NYGy[FF{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nBSFAuOTBizszN M4r3WVczyqCq NIDMfXFKSzVyPUWuOFg2yqEQvF2= M3;qU|I2ODB6OUCw
HepG2 M4faemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXGwOItGPDkEoHi= M4G4Z2ROW00EoB?= MmjCTWM2OD1zMz62OeKhyrIEoECuPVLDqM7:TR?= MW[yOFk6PjF|Nh?=
A549 NHOyN5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mmi5OFjDqGh? M{nOe2ROW00EoB?= M{PlPGlEPTB;MkSxMlnDqMLzwrCzNU4zO8LizszN NHjoSmkzPDl7NkGzOi=>
MCF7 MmqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjlWGpnPDkEoHi= NGHnSIhFVVORwrC= MXXJR|UxRThzLkC5xsDDucLiMUSuNlHDqM7:TR?= NXH2XIhnOjR7OU[xN|Y>
HL-60  NHLkOpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mmn1O|LDqGh? Mlz2TWM2OD1yLkGy5qCG|ryP MXSyOFk6OzBzNB?=
HL-60[R] NFHNVmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4TYclczyqCq NUfoXpIxUUN3ME2zMlEz6oDHzszN M2DmNFI1QTl|MEG0
MIAPACA NYHzT|B{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXjZbmtZT0l3ME2xMlMhyrFiMD6wN{DPxE1? MVmyOFk2Ozh{MR?=
MCF-7 M3fpfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFy1dWFIUTVyPUCuNlUhyrFiMD6xJO69VQ>? NHnxOmczPDl3M{iyNS=>
HeLa MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrHTVUxRTBwNkSgxtEhOC52IN88US=> Mle2NlQ6PTN6MkG=
MO59K  MmjIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDBfIY4KGR? MX7JR|UxRTBwMUhihKXPxE1? M2TyW|I1QTV|NU[x
MO59J NF;XbVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnzBO{Bl NWjwPZNNUUN3ME2wMlHjiIYQvF2= MXGyOFk2OzV4MR?=
ME 180 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITjXJk1QMLiaNMg MmnQTWM2OD16LkpCpOKyyqByLkRihKXPxE1? NHTzV4YzPDl3M{CyOy=>
MCF-7 M4e1Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXlUYQ1QMLiaNMg M1zvbWlEPTB;MkOuPUDDuSByLkRihKXPxE1? MoXJNlQ6PTNyMke=
HeLa NWm1OHkzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;6[XM1QMLiaNMg Mo\5TWM2OD12LkexJOKyKDFwNPMAie69VQ>? NXrSWIJ1OjR7NUOwNlc>
MDA-MB-453 MkLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXi0POKhcMLi MVvJR|UxRTF{LkWgxtEhOC56NfMAie69VQ>? NE\VZ|IzPDl3M{CyOy=>
MDA-MB-231 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVK0W3gyPDkEoHlCpC=> M4XxO2lEPTB;MkSuNlIhyrFiMj65OQKBjc7:TR?= MoXiNlQ6PTNyMke=
PC-3 M1PXO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PUelQ5yqCqwrC= NU\aPIhrUUN3ME2xOE41KMLzIEOuNlPjiIYQvF2= NV[2SVJPOjR7NUOwNlc>
HT-29 NWfXd41lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\tNmdGPDkEoHlCpC=> NF\TZ45KSzVyPUKxMlQ2KMLzIEOuPFfjiIYQvF2= MnzaNlQ6PTNyMke=
BGC-823 M{HFT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\COFjDqGkEoB?= NFm5TIlKSzVyPUSzMlc1KMLzIEWuNVPjiIYQvF2= M37pTlI1Pzl|OEe3
HeLa NUTCV4NrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{WzTFQ5yqCqwrC= MW\JR|UxRTJyOT65NEDDuSBzMz60NkDjiIYQvF2= MoLBNlQ4QTN6N{e=
A549 NHXFbZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfMOFjDqGkEoB?= NIXnTnpKSzVyPUGzPU42PCEEsTC3MlA26oDHzszN NFHRNYgzPDd7M{i3Oy=>
HK-2 NYPmZ5ZjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PDVlQ5yqCqwrC= NWLmS3dxUUN3ME25MlE4KMLzIEGuOVjjiIYQvF2= MVSyOFc6Ozh5Nx?=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p53 / p-p53 / Acetyl-p53 / TF-IIB; 

PubMed: 23800173     


Western blotting analysis of p53 levels and the indicated p53 post-translational modifications in the nucleus and cytoplasm of U-2 OS cells treated with no drug, 1 μmol/l etoposide (treated for 24 hours) and 100 μmol/l etoposide (treated for 12 hours), re䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒ՂĀ鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ뙠ෆ䐺痖暼瘿뙠ෆᾰƌ 뙠ෆÐ㺣

p53 / p21 / c-Myc / PARP ; 

PubMed: 20212154     


Myc is repressed at the posttranscriptional level following etoposide treatment. HEK293 cells were treated with etoposide at the indicated concentrations for 24 h. Parallel samples were taken for western and northern analysis as indicated. 

23800173 20212154
Immunofluorescence
COX IV; 

PubMed: 29221178     


Panel 1 (untreated) depicts the mitochondrial distribution by visualizing the expression of Cox IV in U87(WT) cells. Panel 2 (etoposide treated) represents the distribution of mitochondria in U87(RETO) cells after 10 days of drug exposure as visualized by䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒ՂĀ鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ

γH2AX / pATM ; 

PubMed: 19858003     


HeLa cells were treated with vehicle (Ctl), 6 Gy IR (IR) or 25 μM etoposide (ETO). Co-localization (yellow signal in the overlay (OL)) of gH2AX (red) and pATM (green). Scale bar = 20 μm.

MDC1; 

PubMed: 19858003     


HeLa cells were treated with vehicle (Ctl), 6 Gy IR (IR) or 25 μM etoposide (ETO). Co-localization of gH2AX with MDC1.

pDNA-PKcs; 

PubMed: 19858003     


HeLa cells were treated with vehicle (Ctl), 6 Gy IR (IR) or 25 μM etoposide (ETO). Co-localization of gH2AX with pDNA-PK.

p53; 

PubMed: 27515249     


p53 localization in untreated and 12-h etoposide treated CD41+ MK cells. Cells were stained with anti-p53 antibody. TOTO-3 was used to stain the nucleus. Scale bar=20 μm.

YAP; 

PubMed: 27515249     


(D) YAP localization in untreated CD41+MK cells and CD41+ MK cells treated by 10 μM etoposide for five hours on day 10 of culture. Cells were stained with anti-YAP antibody. DAPI was used to stain the nucleus. Cells (150) were counted and categorized acco䲧疝Ỵ疞㧀疜膉痘 瘿�෋ᾰƌ෋à 㺣痖帉痖Ѐ瑖堘𢡄빢᎒෋à鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ삨Ղ䐺痖暼瘿삨Ղᾰƌ 삨ՂÐ㺣痖삨Ղ€𢡄사Ղ€䀷痗사Ղ౴사Ղ㵶痗사Ղ뺖᎒泌Itemセ᎒Count﫨呂샜Ղ

29221178 19858003 27515249
Growth inhibition assay
Cell viability ; 

PubMed: 22615609     


Effect of etoposide on HEK293 cell viability. Cells were seeded at 104 in 96-well plates and treated with etoposide (50,100,150 and 200µM) for 24 hrs and compared to nontreated cells (control). At the end of treatment period, cell viability was measured u䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒

22615609
In vivo Etoposide administrated as a single agent is found to been ineffective in many xenografts growth, such as Heterotransplanted Hepatoblastoma NMHB1, and NMHB 2, [6] human neuroblastoma xenograft, [7] and human gastrointestinal cancer xenograft, [8] while the dose of 10 mg/kg i.p. Etoposide inhibits murine angiosarcoma cell ISOS-1 tumors in 36% of controls. [2] Etoposide induces tumor immunity in Lewis lung cancer. A single administration of 50 mg/kg Etoposide i.p., induces a 60% survival of C57B1/6 mice injected with Lewis lung cancer cell (3LL) over 60 days. About 40% of these surviving mice reject a subsequent challenge with 3LL, while none of control mice survive beyond 30 days. 3LL cells which have survived an 90% lethal concentration of Etoposide in vitro kill 75% of recipient mice, but 60% surviving mice reject challenge with 3LL. Splenocytes harvested from tumor rejecting mice protect naive mice injected with 3LL. [9]

Protocol

Kinase Assay:[5]
- Collapse

Topoisomerase II activity assay:

Nuclear extracts are prepared, and nuclei are isolated. The activity of topoisomerase II is calculated from the percentage of decatenation obtained. Tritiated kinoplast DNA (KDNA 0.22 μg) is used as a substrate. Etoposide and topoisomerase II are incubated for 30 min at 37 ℃ and are stopped with 1% sodium dodecyl sulfate (SDS) and proteinase K (100 μg/mL). The percentages of decatenation and inhibition of topoisomerase II by Etoposide are obtained.
Cell Research:[5]
- Collapse
  • Cell lines: Human glioma cell lines CL5
  • Concentrations: 80 μg/mL
  • Incubation Time: 1 hour
  • Method: After the Etoposide treatment, cells are removed from the dish with phosphate-buffered saline (PBS) containing 0.03% trypsin and 0.27 mM ethylenediaminetetraacetic acid (EDTA) and are diluted into culture dishes in appropriate numbers to yield between 20 and 200 colonies. After 12 days, cultures are fixed with methanol-acetic acid, stained with crystal violet, and scored for colonies containing more than 50 cells. The standard errors are typically less than 15% of the mean value unless otherwise stated.
    (Only for Reference)
Animal Research:[2]
- Collapse
  • Animal Models: Murine angiosarcoma xenografts ISOS-1
  • Dosages: 10 mg/kg
  • Administration: i.p. every day for 5 days from day 7
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (169.9 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+40% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
15mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 588.56
Formula

C29H32O13

CAS No. 33419-42-0
Storage powder
in solvent
Synonyms VP-16, VP-16213
Smiles CC1OCC2C(O1)C(C(C(O2)OC3C4COC(=O)C4C(C5=CC6=C(C=C35)OCO6)C7=CC(=C(C(=C7)OC)O)OC)O)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Regarding the Etoposide S1225, do you have any data of the inhibition sepcificity of this product? It will inhibit other enzymes other than TOP2A?

  • Answer:

    According to the available published data, the inhibition of Etoposide is specific to TOP2A. But there're also two papers showing that Etoposide could inhibit the p34cdc2 Kinase Activity: 1. http://cancerres.aacrjournals.org/content/52/7/1817.short ; 2. http://cancerres.aacrjournals.org/content/50/12/3761.short.

Tags: buy Etoposide | Etoposide supplier | purchase Etoposide | Etoposide cost | Etoposide manufacturer | order Etoposide | Etoposide distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID